Aptinyx Inc (NASDAQ:APTX) saw unusually-strong trading volume on Monday . Approximately 1,269,936 shares were traded during mid-day trading, an increase of 227% from the previous session’s volume of 388,349 shares.The stock last traded at $3.47 and had previously closed at $3.02.
Several equities analysts recently commented on APTX shares. Cantor Fitzgerald reiterated a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Wednesday, March 27th. Cowen reiterated a “buy” rating on shares of Aptinyx in a research note on Monday. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Aptinyx in a research note on Friday, March 22nd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.95.
The company has a market cap of $105.05 million and a P/E ratio of -1.16.
Aptinyx (NASDAQ:APTX) last posted its earnings results on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.04). The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $1.00 million. Aptinyx had a negative return on equity of 37.53% and a negative net margin of 1,166.40%. As a group, research analysts expect that Aptinyx Inc will post -2.25 earnings per share for the current year.
In related news, Director Henry O. Gosebruch bought 100,000 shares of the company’s stock in a transaction on Wednesday, May 8th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $386,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.47% of the company’s stock.
Several large investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can purchased a new stake in shares of Aptinyx during the fourth quarter worth $40,000. Partner Investment Management L.P. lifted its position in shares of Aptinyx by 4.6% during the fourth quarter. Partner Investment Management L.P. now owns 58,840 shares of the company’s stock worth $973,000 after acquiring an additional 2,570 shares in the last quarter. Barclays PLC lifted its position in shares of Aptinyx by 87.1% during the fourth quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after acquiring an additional 4,340 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Aptinyx by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after acquiring an additional 5,652 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Aptinyx by 71.0% during the fourth quarter. Rhumbline Advisers now owns 16,944 shares of the company’s stock worth $280,000 after acquiring an additional 7,033 shares in the last quarter. Hedge funds and other institutional investors own 58.37% of the company’s stock.
Aptinyx Company Profile (NASDAQ:APTX)
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: Support Level
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.